Similar to APOC3 and ANGPTL4, changes in plasma TG levels through LPL-adjacent variants were associated with a reduced risk of CAD (OR 0.69, P = 1 × 10−24), NAFLD (OR 0.66, P = 0.021), and T2D (OR 0.73, P = 6 × 10−10) (Figure 2B). The gene discussed is ANGPTL4; the disease is metabolic dysfunction-associated steatotic liver disease.